Entering text into the input field will update the search result below

Rigal dry eye disease drug candidate fails Phase 2 trial

Aug. 13, 2014 8:32 AM ETRigel Pharmaceuticals, Inc. (RIGL) StockBy: Douglas W. House, SA News Editor
  • Rigel Pharmaceuticals' (NASDAQ:RIGL) ophthalmic JAK/SYK inhibitor, R348, did not achieve its primary or secondary endpoints in a Phase 2 clinical trial in patients with dry eye disease. The endpoints were: changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo.
  • The company will cease its development of R348 for dry eye disease but will continue its Phase 2 study of dry eye in patients with graft vs host disease (GvHD).
  • Separately, the firm has stopped it indirect AMPK activator program, R118, due to its side-effect profile demonstrated in Phase 1. It will continue its direct AMPK activator research program.
  • Shares are down 9% premarket on modest volume.

Recommended For You

More Trending News

About RIGL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RIGL--
Rigel Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.